Boundless Bio Inc. (BOLD)

Over the past six months, Boundless Bio, Inc.'s stock price has been impacted by several events, including the release of financial results, participation in healthcare conferences, and updates on its drug development programs. The stock has experienced a decline of 34.3% over the past 12 months. In November 2025, the company reported its Third Quarter 2025 Financial Results and Business Highlights, noting ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial and an expected IND submission for BBI-940 in the first half of 2026. In December 2025, Boundless Bio participated in the Piper Sandler 37th Annual Healthcare Conference. In January 2026, the company announced it was advancing its novel Kinesin degrader program BBI-940 and extending its cash runway. In February 2026, Boundless Bio participated in the Guggenheim Emerging Outlook: Biotech Summit 2026. In March 2026, the company announced participation in the Leerink Global Healthcare Conference and reported its Fourth Quarter and Full Year 2025 Financial Results and Business Highlights, beating analyst estimates for its Q4 loss. Also in March 2026, Boundless Bio announced an upcoming presentation of its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026, and an article on Seeking Alpha highlighted Boundless Bio as an "Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader."

As a clinical-stage oncology company, Boundless Bio, Inc. does not currently have commercialized products or services; therefore, there is no information available regarding demand seasonality for its products or services.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing cancer therapeutics for patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA). The company utilizes its Spyglass platform to identify targets essential for ecDNA functionality and develops small molecule drugs to inhibit these targets. Its major product candidates include BBI-355, a CHK1 inhibitor in Phase 1/2 trial; BBI-825, an RNR inhibitor which was evaluated in a Phase 1/2 clinical trial but not advanced due to pharmacokinetic exposure observations; and BBI-940, a Kinesin degrader in Phase 1/2 trial.

Boundless Bio, Inc. is headquartered in San Diego, California, and was incorporated in Delaware.

Boundless Bio, Inc. maintains its brand reputation through its focus on innovative oncology research and active participation in the scientific and investor communities. The company regularly issues press releases detailing financial results, research and development milestones, and its involvement in prominent healthcare and oncology conferences. There have been no specific events reported in the past year that have negatively impacted Boundless Bio, Inc.'s brand reputation.

Boundless Bio, Inc.'s stock ownership is a mix of institutional, retail, and individual investors. Approximately 20.60% to 23.46% of the company's stock is owned by Institutional Investors, 8.19% by Insiders, and a significant portion (68.35%) by Public Companies and Individual Investors. Major institutional owners and shareholders include Fmr Llc, Citadel Advisors Llc, Stonepine Capital Management, LLC, Sectoral Asset Management Inc, Vanguard Group Inc, Wellington Management Group Llp, Renaissance Technologies Llc, Alyeska Investment Group, L.P., Arch Venture Partners, L.P., and Bayer Aktiengesellschaft. Peter Kolchinsky is noted as owning the most shares among individual investors.